Julia Alterman to Huntington Disease
This is a "connection" page, showing publications Julia Alterman has written about Huntington Disease.
Connection Strength
0.721
-
Papadopoulou AS, Alterman J, Landles C, Smith EJ, Conroy F, Phillips J, Canibano-Pico M, Nita IM, Osborne GF, Iqbal A, Aldous SG, Bondulich MK, Gomez-Paredes C, Sathasivam K, O'Reilly D, Echeverria D, Bobkov K, Greene JR, Aronin N, Khvorova A, Bates GP. Lowering the HTT1a transcript as an effective therapy for Huntington's disease in a knockin mouse model. Sci Transl Med. 2026 Mar 18; 18(841):eadw2495.
Score: 0.212
-
Conroy F, Miller R, Alterman JF, Hassler MR, Echeverria D, Godinho BMDC, Knox EG, Sapp E, Sousa J, Yamada K, Mahmood F, Boudi A, Kegel-Gleason K, DiFiglia M, Aronin N, Khvorova A, Pfister EL. Chemical engineering of therapeutic siRNAs for allele-specific gene silencing in Huntington's disease models. Nat Commun. 2022 10 03; 13(1):5802.
Score: 0.167
-
Yamada K, Hildebrand S, Davis SM, Miller R, Conroy F, Sapp E, Caiazzi J, Alterman JF, Roux L, Echeverria D, Hassler MR, Pfister EL, DiFiglia M, Aronin N, Khvorova A. Structurally constrained phosphonate internucleotide linkage impacts oligonucleotide-enzyme interaction, and modulates siRNA activity and allele specificity. Nucleic Acids Res. 2021 12 02; 49(21):12069-12088.
Score: 0.158
-
McAdam RL, Morton A, Gordon SL, Alterman JF, Khvorova A, Cousin MA, Smillie KJ. Loss of huntingtin function slows synaptic vesicle endocytosis in striatal neurons from the httQ140/Q140 mouse model of Huntington's disease. Neurobiol Dis. 2020 02; 134:104637.
Score: 0.136
-
Belgrad J, Tang Q, Hildebrand S, Summers A, Sapp E, Echeverria D, O'Reilly D, Luu E, Bramato B, Allen S, Cooper D, Alterman J, Yamada K, Aronin N, DiFiglia M, Khvorova A. A programmable dual-targeting siRNA scaffold supports potent two-gene modulation in the central nervous system. Nucleic Acids Res. 2024 06 24; 52(11):6099-6113.
Score: 0.047